Icahn Enterprises IEP Pharma — Selling General And Administrative Expense
Other segment segments
Other financials
Where this comes from
Reported directly by Icahn Enterprises in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The official record: Icahn Enterprises’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Icahn Enterprises's pharma — selling general and administrative expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Icahn Enterprises's pharma — selling general and administrative expense?
- Icahn Enterprises (IEP) reported pharma — selling general and administrative expense of $14M in Q1 2026.
- How has Icahn Enterprises's pharma — selling general and administrative expense changed year-over-year?
- Icahn Enterprises's pharma — selling general and administrative expense increased by 7.7% year-over-year, from $13M to $14M.
- What is the long-term trend for Icahn Enterprises's pharma — selling general and administrative expense?
- Over 4 years (2021 to 2025), Icahn Enterprises's pharma — selling general and administrative expense has grown at a 6.6% compound annual growth rate (CAGR), from $38M to $49M.
- What does pharma — selling general and administrative expense mean?
- The total operating expenses incurred by the pharmaceutical segment for non-production activities, including marketing, sales force support, and general corporate administration. This metric helps investors assess the segment's operational overhead and cost control discipline.